A5037629427- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Single-cell and spatial transcriptomics
- Biosimilars and Bioanalytical Methods
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Advancements in Semiconductor Devices and Circuit Design
- Cancer Genomics and Diagnostics
- Biomedical Ethics and Regulation
- Breast Cancer Treatment Studies
- Silicon Carbide Semiconductor Technologies
- Virus-based gene therapy research
- Cutaneous lymphoproliferative disorders research
- Integrated Circuits and Semiconductor Failure Analysis
- Lung Cancer Treatments and Mutations
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
Mayo Clinic in Arizona
2016-2025
WinnMed
2016-2024
Mayo Clinic
2015-2024
University of Hong Kong
2024
King Faisal Specialist Hospital & Research Centre
2023
Memorial Sloan Kettering Cancer Center
2022
Palmetto Hematology Oncology
2015-2016
Ministério da Saúde
2014
Fundação Oswaldo Cruz
2008-2014
University of Miami
2011-2012
We report the emergence of leptospirosis-associated severe pulmonary hemorrhagic syndrome (SPHS) in slum communities Salvador, Brazil. Although active surveillance did not identify SPHS before 2003, 47 cases were identified from 2003 through 2005; case-fatality rate was 74%. By 2005, caused 55% deaths due to leptospirosis.
Exhausted T-cells in follicular lymphoma (FL) typically express PD-1, but expression of PD-1 is not limited to exhausted cells. Although expected be functionally suppressed, we found that the population intratumoral PD-1+ T cells were predominantly responsible for production cytokines and granules. This surprising finding prompted us explore involvement LAG-3 specifically identify We was expressed on a subset from FL LAG-3+ almost exclusively came population. CyTOF analysis revealed...
<h3>Background</h3> Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple subtypes of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. <h3>Patients and methods</h3> This phase II study (ELM-2; NCT03888105) evaluated odronextamab in patients with R/R follicular lymphoma after two or more lines systemic therapy. Patients received intravenous 21-day cycles, step-up dosing cycle 1 help...
Uveal melanoma is a rare type of melanoma, with only five to seven cases per one million persons diagnosed each year. Patients metastatic uveal origin tend have lower response rates on traditional therapies. Herein we report our experience 10 patients (MUM) who received pembrolizumab. Eligible were more than or equal 18 years old, had unresectable MUM, progressed prior ipilimumab therapy, good performance status (Eastern Cooperative Oncology Group 0 1), and adequate organ marrow function....
ADAM10 and ADAM17 expression soluble PD-L1 (sPD-L1) predict poor prognosis in many malignancies, including patients treated with PD-(L)1 inhibitors. The mechanism of production its effects are unknown. Here we uncover a novel ADAM10- ADAM17-mediated resistance to cleave from the surface malignant cells extracellular vesicles. This cleavage produces an active sPD-L1 fragment that induces apoptosis CD8 + T compromises killing tumor by cells. Reduced site protein-to-mRNA ratios outcomes...
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated mixed outcomes in small cohorts of patients relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI efficacy more definitively this population, we retrospectively evaluated clinical a large cohort 96 receiving failure across 15 US academic centers. Most (53%) had diffuse lymphoma, were treated axicabtagene ciloleucel (53%), early (≤180 days) (83%), and received pembrolizumab (49%) or nivolumab...
Treatment with programmed death-1 (PD-1) blocking antibodies results in high overall response rates refractory and relapsed classical Hodgkin lymphoma (cHL) patients, indicating that PD-1/PD-1 ligand interactions are integral to progression of this disease. Given the genetically driven increased PD-L1/2 expression HL, we hypothesized reverse signaling through PD-1 ligands may be a potential mechanism contributing growth survival Reed-Sternberg (HRS) cells cHL. Our data show engagement PD-L1...
Thyroid lymphoma is a relatively rare disease often posing diagnostic challenge. Reaching the final diagnosis can be delayed if insufficient biopsy material obtained for immunohistochemistry analysis. The aim of this study was to evaluate clinical, biochemical, and radiological features thyroid lymphoma.A retrospective analysis conducted all Mayo Clinic patients evaluated between 2000 2014 who had tissue positive lymphoma.Seventy-five subjects biopsy-proven lymphoma, 62.7% were primary...
Follicular lymphoma (FL) is an indolent B cell malignancy characterized by extensive but poorly functional T infiltrate in the tumor microenvironment. Using mass cytometry, we identified at least 12 subsets of intratumoral CD4+ cells, 3 which were unique to FL biopsies versus control tissues. Of these subsets, frequency naive cells correlated with improved patient survival. Although total PD-1+ numbers not associated outcome, specific subpopulations poor Intratumoral lacking CD27 and CD28...
Abstract High‐dimensional mass cytometry data potentially enable a comprehensive characterization of immune cells. In order to positively affect clinical trials and translational research, this advanced technology needs demonstrate high reproducibility results across multiple sites for both peripheral blood mononuclear cells (PBMC) whole preparations. A dry 30‐marker broad immunophenotyping panel customized automated analysis software were recently engineered are commercially available as...
Abstract Despite a characteristic indolent course, substantial subset of follicular lymphoma (FL) patients has an early relapse with poor outcome. Cells in the microenvironment may be key contributor to treatment failure. We used discovery and validation study design identify microenvironmental determinants failure then integrated these results into FLIPI. In total, 496 newly diagnosed FL grade 1–3 A who were prospectively enrolled MER cohort from 2002 2012 evaluated. Tissue microarrays...
Analyze the pattern of disease failure after anti-CD19-directed chimeric antigen receptor T-cell therapy (CART) for non-Hodgkin lymphoma, assess local control rate bridging radiotherapy (bRT) and characterize in-field recurrences.We retrospectively reviewed 120 patients with NHL who received CART between 2018 2020. Baseline characteristics treatment outcomes were compared bRT those did not (noRT).Of 118 included, 14 (12%) bRT, while 104 (88%) not. group had more localized extranodal disease....
Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to date been anecdotal. Here, we conducted a phase 1 clinical trial of systemic OV therapy and investigated the mechanisms action in responding T-cell lymphoma (TCL) patients. A single IV dose VSV-IFNβ-NIS was administered patients relapsed refractory hematologic malignancies determine safety efficacy across 4 levels (DL). Correlative studies were undertaken evaluate viremia, virus shedding, replication immune responses....
It is unknown whether serum procalcitonin (PCT) concentration monitoring can differentiate between bacterial infection or cytokine release syndrome (CRS) when chimeric antigen receptor T-cell (CAR-T) recipients present with a constellation of signs and symptoms that may represent both complications.The objective the study was to assess utility PCT concentrations as biomarker in CAR-T recipients.This single-center, retrospective, medical record review evaluated patients prescribed therapy...
Follicular lymphoma (FL) is an indolent non-Hodgkin of germinal center origin, which presents with significant biologic and clinical heterogeneity. Using RNA-seq on B cells sorted from 87 FL biopsies, combined machine-learning approaches, we identify 3 transcriptional states that divide the biological ontology into inflamed, proliferative, chromatin-modifying states, relationship to prior GC cell phenotypes. When integrated whole-exome sequencing immune profiling, find each state was...
Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy agents target the PROGRAMMED DEATH 1 (PD-1) receptor demonstrated clinical activity durable responses in early-phase trials this patient population; however, patients history of stem cell transplantation (SCT) were intentionally excluded from participation those studies due to concerns for reactivation graft-versus-host...
Signal regulatory protein-α (SIRPα) is a key member of the "do-not-eat-me" signaling pathway, but its biological role and clinical relevance in B-cell NHL relatively unknown. Using biopsy specimens from follicular lymphoma (FL), we identified three subsets (CD14+SIRPαhi, CD14-SIRPαlow, CD14-SIRPαneg) monocyte/macrophages (Mo/MΦ) based on CD14 SIRPα expression. CD14+SIRPαhi cells expressed common Mo/MΦ markers; exhibited characteristic differentiation, migration, phagocytosis; suppressed...
Histological transformation in Waldenström macroglobulinemia (WM) is an uncommon complication, with limited data, particularly regarding the impact of MYD88 L265P mutation on transformation. We examined risk factors and outcomes associated WM, highlighting role mutation. Patients WM seen at Mayo Clinic, Rochester, USA University Hospital Reims, France, between 01/01/1996 December 31, 2017 were included; 50 (4.3%) 1147 patients transformed to a high-grade lymphoma, median...